Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1922041

Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Description:

Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Glaucoma Therapeutics market. The report identifies the key trends shaping and driving the global Glaucoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Glaucoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Glaucoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Glaucoma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Glaucoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Glaucoma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Glaucoma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Glaucoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Glaucoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Glaucoma Therapeutics market landscape? – Identify, understand and capitalize.

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Glaucoma Therapeutics: Introduction
2.1 Overview
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.3.1 Global
2.3.2 The US
2.3.3 The UK
2.3.4 Spain
2.3.5 Germany
2.3.6 France
2.3.7 Italy
2.3.8 Japan
2.3.9 Pharmaco-economic Burden
2.3.10 Quality of Life (QoL)
2.4 Symptoms
2.5 Diagnosis
2.5.1 Patient History
2.5.2 Tonometry
2.5.3 Pachymetery
2.5.4 Ophthalmoscope
2.5.5 Visual Activity Measurement
2.6 Treatment and Management Pattern
2.6.1 Treatment Options
2.6.2 Management Protocol
2.6.3 Prognosis and Follow-up
2.7 Referral Pathway
2.8 Pipeline Report Guidance
3 Glaucoma Therapeutics: Market Characterization
3.1 Overview
3.2 Glaucoma Therapeutics Market Size
3.3 Glaucoma Therapeutics Market Size (2005-2010) – Global
3.4 Glaucoma Therapeutics Market Forecast (2010-2018) – Global
3.5 Glaucoma Therapeutics Market Size (2005-2010) –The US
3.6 Glaucoma Therapeutics Market Forecast (2010-2018) – The US
3.7 Glaucoma Therapeutics Market Size (2005-2010) – France
3.8 Glaucoma Therapeutics Market Forecast (2010-2018) – France
3.9 Glaucoma Therapeutics Market Size (2005-2010) –Germany
3.10 Glaucoma Therapeutics Market Forecast (2010-2018) – Germany
3.11 Glaucoma Therapeutics Market Size (2005-2010) – Italy
3.12 Glaucoma Therapeutics Market Forecast (2010-2018) – Italy
3.13 Glaucoma Therapeutics Market Size (2005-2010) – Spain
3.14 Glaucoma Therapeutics Market Forecast (2010-2018) – Spain
3.15 Glaucoma Therapeutics Market Size (2005-2010) – The UK
3.16 Glaucoma Therapeutics Market Forecast (2010-2018) – The UK
3.17 Glaucoma Therapeutics Market Size (2005-2010) – Japan
3.18 Glaucoma Therapeutics Market Forecast (2010-2018) – Japan
3.19 Drivers and Barriers
3.19.1 Drivers of the Glaucoma Market
3.19.2 Barriers for the Glaucoma Market
3.20 Opportunity and Unmet needs
3.21 Key Takeaway
4 Glaucoma Therapeutics Market – Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Glaucoma Therapeutics market
4.3.1 Alphagan P (0.1% and 0.15% brimonidine tartrate ophthalmic solution)
4.3.2 Travatan Z (0.004% travoprost)
4.3.3 Lumigan (0.01% and 0.03% bimatoprost)
4.3.4 Combigan (0.2% brimonidine tartrate and 0.5% timolol maleate)
4.3.5 Istalol (0.5% timolol maleate)
4.3.6 Xalatan (latanoprost)
4.4 Key Takeaway
5 Glaucoma Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline by Phases of Development
5.3.1 Glaucoma Therapeutics – NDA Filed Pipeline
5.3.2 Glaucoma Therapeutics – Phase III Pipeline
5.3.3 Glaucoma Therapeutics – Phase II Pipeline
5.3.4 Glaucoma Therapeutics – Phase I Pipeline
5.3.5 Glaucoma Therapeutics – Pre-Clinical Pipeline
5.3.6 Glaucoma Therapeutics – Discovery Pipeline
5.4 Glaucoma Therapeutics Market – Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Promising Drugs under Development
5.7 Profile for Promising Drugs
5.7.1 Saflutan (tafluprost)
5.7.2 DuoTrav APS
5.7.3 SNJ-2022
5.7.4 T2345
5.7.5 Azarga
5.7.6 BKC Latanoprost
5.8 Key Takeaway
6 Glaucoma Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Therapeutic Clinical Trials
7 Glaucoma Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Glaucoma Therapeutics Market: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Merck & Co., Inc
8.2.2 Alcon/Novartis AG
8.2.3 Allergan, Inc.
8.2.4 Senju Pharmaceuticals Co. Ltd
8.2.5 Santen Pharmaceuticals Co.Ltd
8.2.6 Sun Pharmaceuticals Industries Ltd
8.3 Other Companies in the Glaucoma Therapeutics Market
9 Glaucoma Therapeutics: Liscensing and Partnership Deals
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Glaucoma Types
Table 2: Glaucoma Therapeutics – Diagnostic Indicators
Table 3: Pharmacological Treatment Options for the Treatment of Glaucoma
Table 4: Glaucoma Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 5: Glaucoma Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 6: Glaucoma Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 7: Glaucoma Therapeutics Market, the US, Forecast ($m), 2010-2018
Table 8: Glaucoma Therapeutics Market, France, Revenue ($m), 2005-2010
Table 9: Glaucoma Therapeutics Market, France, Forecast ($m), 2010-2018
Table 10: Glaucoma Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 11: Glaucoma Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 12: Glaucoma Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Glaucoma Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 14: Glaucoma Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Glaucoma Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 16: Glaucoma Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 17: Glaucoma Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 18: Glaucoma Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 19: Glaucoma Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 20: Xalatan Clinical Trial Results
Table 21: Glaucoma Therapeutics – NDA Filed Pipeline, 2011
Table 22: Glaucoma Therapeutics – Phase III Pipeline, 2011
Table 23: Glaucoma Therapeutics – Phase II Pipeline, 2011
Table 24: Glaucoma Therapeutics – Phase I Pipeline, 2011
Table 25: Glaucoma Therapeutics – Pre Clinical Pipeline, 2011
Table 26: Glaucoma Therapeutics – Discovery Pipeline, 2011
Table 27: Glaucoma Therapeutics – Most Promising Drugs Under Development, 2011
Table 28: Glaucoma Therapeutics – Clinical Trials by Region, 2011
Table 29: Glaucoma Therapeutics – Clinical Trials by Phase of Development, 2011
Table 30: Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2011
Table 31: Glaucoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
Table 32: Glaucoma Therapeutics, Global, Clinical Trials by Top Companies, 2011
Table 33: Merck Pharmaceuticals - Ophthalmology Pipeline, 2010
Table 34: Alcon/Novartis– Glaucoma Pipeline, 2010
Table 35: Ophthalmic Therapeutics, Allergan, Pipeline, 2011
Table 36: Glaucoma Therapeutics, Allergan, Pipeline, 2011
Table 37: Opthalmology Therapeutics, Senju Pipeline, 2011
Table 38: Glaucoma Therapeutics, Senju Pipeline, 2011
Table 39: Glaucoma Therapeutics, Santen Pipeline, 2011
Table 40: Glaucoma Therapeutics, Santen Pipeline, 2011
Table 41: Glaucoma Therapeutics, Sun Pharmaceuticals, Pipeline, 2011
Table 42: Glaucoma Therapeutics, Sun Pharmaceuticals, Pipeline, 2011
Table 43: Glaucoma Therapeutics Market – Future Players, 2011
Table 44: Glaucoma Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures
Figure 1: Glaucoma – Representation of Intraocular Pressure Increase in the Eye
Figure 2: Principle for Estimating Target IOP
Figure 3: Glaucoma Therapeutics – Pathophysiology
Figure 4: Pictorial Presentation – Potential Causes of RGC Death in Glaucoma
Figure 5: Pictorial Representation of the Glaucoma Trend in the Disease Progression in the Trabecular Meshwork
Figure 6: Glaucoma Therapeutics – Treatment And Management
Figure 7: Referral Pathway for Glaucoma Disease
Figure 8: Glaucoma Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 9: Glaucoma Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 10: Glaucoma Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 11: Glaucoma Therapeutics Market, the US, Forecast ($m), 2010-2018
Figure 12: Glaucoma Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 13: Glaucoma Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 14: Glaucoma Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 15: Glaucoma Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 16: Glaucoma Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 17: Glaucoma Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 18: Glaucoma Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 19: Glaucoma Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 20: Glaucoma Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 21: Glaucoma Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 22: Glaucoma Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 23: Glaucoma Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 24: Opportunity and Unmet Need in the Glaucoma Therapeutics Market, 2011
Figure 25: Glaucoma Therapeutics, Strategic Competitor Assessment, 2011
Figure 26: Glaucoma Therapeutics Pipeline by Phase of Development, 2011
Figure 27: Glaucoma Therapeutics Market – Pipeline by Mechanism of Action, 2011
Figure 28: Technology Trends Analytic Framework of the Glaucoma Therapeutics Pipeline, 2011
Figure 29: Technology Trends Analytic Framework of the Glaucoma Therapeutics Pipeline – Description, 2011
Figure 30: Saflutan (tafluprost) – Clinical Study Details
Figure 31: DuoTrav APS – Clinical Study Details
Figure 32: T2345–Clinical Trial Details
Figure 33: Azarga – Clinical Study Details
Figure 34: BKC Latanoprost – Clinical Study Details
Figure 35: Glaucoma Therapeutics – Clinical Trials by Region, 2011
Figure 36: Glaucoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Figure 37: Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2011
Figure 38: Glaucoma Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011
Figure 39: Glaucoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
Figure 40: Glaucoma Therapeutics, Global, Clinical Trials by Top Companies, 2011
Figure 41: Glaucoma Therapeutics, Drivers and Barriers, 2011
Figure 42: Implications for Future Market Competition in the Glaucoma, 2011
Figure 43: Glaucoma Therapeutics Market – Clinical Pipeline by Company, 2011

Companies Mentioned

Merck & Co., Inc
Alcon/Novartis AG
Allergan, Inc.
Senju Pharmaceuticals Co. Ltd
Santen Pharmaceuticals Co.Ltd
Sun Pharmaceuticals Industries Ltd

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Wednesday, May 22, 2013
5:10:25 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Web Address

http://www.researchandmarkets.com/reports/1922041

Office Code

OC8DIQSPPRURPZ

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 2,690.00
Electronic (PDF) - Site License		EURO€ 5,381.00
Electronic (PDF) - Enterprisewide		EURO€ 8,071.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Wednesday, May 22, 2013
5:10:25 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)